Sanofi (NASDAQ:SNY) Receives Average Rating of "Buy" from Analysts

Key Points

• Sanofi has received an average analyst rating of "Buy", with ten research firms evaluating the stock - one hold, six buy, and three strong buy ratings.
• The average 1-year price target for Sanofi among brokerages is $62.67, indicating potential growth from its current share price of around $47.65.
• Sanofi reported a quarterly earnings per share (EPS) of $0.90, which fell short of analysts' expectations of $0.96, but its revenue of $11.34 billion outperformed estimates.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been given an average rating of "Buy" by the ten research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $62.6667.

A number of analysts have recently commented on the stock. Barclays reissued an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd.

Sanofi Stock Performance

Shares of SNY stock opened at $47.65 on Friday. The company's fifty day simple moving average is $48.68 and its 200-day simple moving average is $51.21. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The firm has a market cap of $117.01 billion, a PE ratio of 11.45, a P/E/G ratio of 1.12 and a beta of 0.51. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 EPS. Equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Trading of Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Accent Capital Management LLC bought a new stake in Sanofi during the first quarter worth $29,000. Eastern Bank raised its position in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after acquiring an additional 300 shares in the last quarter. Ameritas Advisory Services LLC bought a new stake in Sanofi during the second quarter worth $28,000. Golden State Wealth Management LLC raised its position in shares of Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares during the period. Finally, Banque Transatlantique SA bought a new position in shares of Sanofi in the first quarter valued at about $33,000. 14.04% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.